Expert Video - What are the special considerations in treating frail elderly AML patients?
Dr. Barry Skikne, an expert on acute myeloid leukemia (AML) at the University of Kansas Medical Center in Kansas City, talks about some of the special considerations for treating frail elderly AML patients. Tolerability to intensive chemotherapy is challenging in frail elderly patients, and patients will quite often require hospitalization involving continuous intravenous infusion over 4 to 5 days with recovery lasting over 4-5 weeks. Elderly frail patients are closely observed for complications, especially if they have underlying heart, lung, or kidney disease. Less intensive treatment should be a consideration in frail elderly patients. Elderly patients can benefit from outpatient management. New oral treatments are being introduced which are more convenient for patients. Standard treatments such as azacitidine and decitabine may be given in combination; newer regimens present opportunities for treating elderly AML patients.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.